Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Rhea-AI Summary
Can-Fite (NYSE American: CANF) reported Phase 2a results for Namodenoson in advanced pancreatic ductal adenocarcinoma. The 20‑patient, open-label study met its primary safety endpoint, with Namodenoson well tolerated.
In eight evaluable third-line patients, median overall survival exceeded five months, with durable disease control and two patients still alive. One second-line patient remains alive beyond 18 months. Can-Fite plans a Phase 2b combination study with chemotherapy, supported by preclinical data showing Namodenoson enhances chemotherapeutic anti-tumor activity.
Positive
- Phase 2a trial met its primary safety endpoint for Namodenoson
- Namodenoson showed a safety profile consistent with prior clinical trials
- In eight evaluable third-line patients, median overall survival exceeded five months
- 62.5% of evaluable third-line patients survived at least five months
- One second-line patient remains alive more than 18 months after Namodenoson initiation
- Plans to advance Namodenoson into Phase 2b combination study with chemotherapy
Negative
- Phase 2a study was open-label with a small total enrollment of 20 patients
- Updated survival analysis in third-line setting included only eight of fourteen patients
News Market Reaction – CANF
In the Jul 1 session, CANF gained 55.89%, reflecting a significant positive market reaction. Argus tracked a peak move of +137.6% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 26 | Patent allowance | Positive | -6.5% | Japan patent allowance for Namodenoson anti-obesity technology expanding IP estate. |
| Jun 22 | Scientific article | Positive | +6.7% | Peer-reviewed article on broad therapeutic potential of A3AR agonists. |
| Jun 17 | Conference presentation | Neutral | +1.0% | Plans to present late-stage pipeline and licensing at BIO Convention 2026. |
| Jun 02 | Clinical update | Positive | -4.0% | Encouraging Phase 2a pancreatic cancer observations and RAS pathway mechanism data. |
| May 18 | Vet publication | Positive | -3.0% | Peer-reviewed Piclidenoson canine osteoarthritis data and sizeable Vetbiolix deal. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CANF news often receives mixed reactions, with several positive clinical or IP updates followed by negative price moves, suggesting frequent divergences between news tone and near-term trading.
Key Terms
pancreatic ductal adenocarcinoma medical
overall survival medical
progression-free survival medical
wnt/β-catenin medical
hedgehog signalling medical
multidrug-resistance proteins medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months
Ramat Gan, Israel, July 01, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes.
The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth-line treatment. Namodenoson was well tolerated, with a safety profile consistent with prior clinical trials.
Following extended follow-up, an updated survival analysis was performed in the third-line population, focusing on the eight patients who survived at least two months after treatment initiation, thereby excluding patients with rapidly progressive disease unlikely to derive benefit from systemic therapy.
Among the eight evaluable third-line patients:
• Median overall survival exceeded 5 months
•
•
• Two patients remain alive at the data cutoff, including one patient continuing treatment and another followed for almost nine months
• Durable disease control was observed, including progression-free survival extending beyond seven months.
The findings identify a subset of heavily pretreated pancreatic cancer patients achieving prolonged survival despite receiving Namodenoson as third-line therapy, supporting further clinical development of Namodenoson.
Notably, among the five patients treated in the second-line setting, one patient remains alive more than 18 months after initiation of Namodenoson therapy, representing the longest survivor in the study.
Prof. Salomon Stemmer, who is leading the Phase 2a study and is an oncology key opinion leader and Professor at the Davidoff Institute of Oncology, Rabin Medical Center, Israel, commented: “Pancreatic cancer remains one of the most difficult malignancies to treat, particularly after failure of standard therapies. The results of Namodenoson monotherapy are impressive and the favorable safety profile together with the prolonged survival observed in a subgroup of patients, suggest biological activity worthy of further investigation. Based on these findings and the growing preclinical evidence demonstrating enhancement of chemotherapy activity, I believe the next logical step is evaluation of Namodenoson in combination with chemotherapy."
Based on these findings and discussions with the study's principal investigator, Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy. The decision follows recently published peer-reviewed preclinical data demonstrating that Namodenoson (2-Cl-IB-MECA) enhances the anti-tumor activity of chemotherapeutic agents in pancreatic cancer models by simultaneously inhibiting multiple tumor proliferation and drug-resistance pathways, including Wnt/β-catenin and Hedgehog signalling, while reducing expression of multidrug-resistance proteins. The publication further demonstrated that Namodenoson increased chemosensitivity in pancreatic cancer cells, providing a strong mechanistic rationale for combination therapy
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and is enrolling patients in a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts and plans to advance Namodenoson into a combination study. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
